Emerging systemic treatment perspectives on brain metastases: moving toward a better outlook for patients
C Alvarez-Breckenridge, J Remon, Y Piña… - American Society of …, 2022 - ascopubs.org
The diagnosis of brain metastases has historically been a dreaded, end-stage complication
of systemic disease. Additionally, with the increasing effectiveness of systemic therapies that …
of systemic disease. Additionally, with the increasing effectiveness of systemic therapies that …
A need for more molecular profiling in brain metastases
E Shen, AED Van Swearingen, MJ Price… - Frontiers in …, 2022 - frontiersin.org
As local disease control improves, the public health impact of brain metastases (BrM)
continues to grow. Molecular features are frequently different between primary and …
continues to grow. Molecular features are frequently different between primary and …
[HTML][HTML] Heterogeneous expression of predictive biomarkers PD-L1 and TIGIT in non-mucinous lung adenocarcinoma and corresponding lymph node metastasis: A …
T Kolb, J Benckendorff, P Möller, TFE Barth… - Neoplasia, 2023 - Elsevier
The use of immune checkpoint inhibitors (ICI) targeting the PD-L1: PD1 interaction
revolutionized tumor treatment by re-activating the anti-tumoral capacity of the immune …
revolutionized tumor treatment by re-activating the anti-tumoral capacity of the immune …
[HTML][HTML] Multi-omics consensus portfolio to refine the classification of lung adenocarcinoma with prognostic stratification, tumor microenvironment, and unique …
Y Zou, C Cao, Y Wang, Y Zhou, S Yao… - Translational Lung …, 2022 - ncbi.nlm.nih.gov
Background Molecular classification of lung adenocarcinoma (LUAD) based on
transcriptomic features has been widely studied. The complementarity of data obtained from …
transcriptomic features has been widely studied. The complementarity of data obtained from …
Genomic landscape and actionable mutations of brain metastases derived from non–small cell lung cancer: A systematic review
LJ Andrews, ZA Thornton, R Saleh… - Neuro-Oncology …, 2023 - academic.oup.com
Background Brain metastases derived from non–small cell lung cancer (NSCLC) represent
a significant clinical problem. We aim to characterize the genomic landscape of brain …
a significant clinical problem. We aim to characterize the genomic landscape of brain …
Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non–Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With …
PURPOSE Local consolidative therapy (LCT) for patients with synchronous oligometastatic
non–small-cell lung cancer is an evolving treatment strategy, but outcomes following LCT …
non–small-cell lung cancer is an evolving treatment strategy, but outcomes following LCT …
Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non‐small cell lung cancer
S Chen, W Huang, Z Liu, M Jin, J Li, L Meng… - Cancer …, 2023 - Wiley Online Library
Abstract Background Most Non‐small cell lung cancer (NSCLC) patients tend to have
metastases at the initial diagnosis. However, limited knowledge has been established …
metastases at the initial diagnosis. However, limited knowledge has been established …
In vivo screening of tumor-hepatocyte interactions identifies Plexin B2 as a gatekeeper of liver metastasis
It is estimated that only 0.02% of disseminated tumor cells are able to seed overt
metastases. While this indicates the presence of environmental constraints to metastatic …
metastases. While this indicates the presence of environmental constraints to metastatic …
[PDF][PDF] Neuro-Oncology Advances
LJ Andrews, ZA Thornton, R Saleh, S Dawson… - 2023 - core.ac.uk
Background. Brain metastases derived from non–small cell lung cancer (NSCLC) represent
a significant clinical problem. We aim to characterize the genomic landscape of brain …
a significant clinical problem. We aim to characterize the genomic landscape of brain …
Молекулярні біомаркери в менеджменті пацієнтів з недрібноклітинним раком легень
O Sulaieva, O Pototska, D Kozakov… - Practical …, 2024 - oncology.zaslavsky.com.ua
Недрібноклітинний рак легень (НДКРЛ) є одною з провідних причин смертності в
онкології. Упровадження в клінічну практику таргетної терапії та імунотерапії дозволило …
онкології. Упровадження в клінічну практику таргетної терапії та імунотерапії дозволило …